Myelodysplastic syndrome
Not recruitingStudy on Luspatercept and Epoetin Alfa for Treating Anemia in Patients with Low to Intermediate Risk Myelodysplastic Syndromes Needing Blood Transfusions
Study on Luspatercept and Epoetin Alfa for Treating Anemia in Patients with Low to Intermediate Risk Myelodysplastic Syndromes Needing Blood Transfusions
- Disease:Myelodysplastic syndrome
- Substances:Epoetin AlfaLuspatercept
Hungary- Participants:18–64 years · 65+ years
- Substances:Epoetin Alfa
- Sponsor:Celgene Corp.














